Join the Veozah group to help and get support from people like you.
Veozah News
FDA: Veozah, First Hormone-Free Hot Flash Drug, Issued Black Box Warning
WEDNESDAY, Dec. 18, 2024 – The U.S. Food and Drug Administration (FDA) has issued its most serious warning – a black-box warning – for Veozah, a medication used to relieve hot flashes in...
FDA Medwatch Alert: FDA Adds Boxed Warning to Veozah (fezolinetant) to Highlight the Known Risk of Rare But Serious Liver Injury
Update: December 16, 2024FDA adds a Boxed Warning, our most prominent warning, to highlight the known risk of rare but serious liver injury associated with use of menopause medicine Veozah...
FDA Medwatch Alert: Drug Safety Communication: FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (fezolinetant) for Hot Flashes Due to Menopause
September 12, 2024 – The FDA is warning that Veozah (fezolinetant), a medicine used to treat hot flashes due to menopause, can cause rare but serious liver injury. If there are signs and symptoms ...
Fezolinetant Safe, Effective for Moderate-to-Severe Menopause Hot Flashes
MONDAY, May 20, 2024 – Fezolinetant is safe and effective for moderate-to-severe vasomotor symptoms (VMS), according to a study presented at the annual European Congress of Endocrinology, hosted by...
FDA Approves Veozah (fezolinetant) for the Treatment of Vasomotor Symptoms Due to Menopause
TOKYO, May 13 2023 – Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Veozah (fezolinetant) 45 mg once daily for the treatment of moderate to severe v...
Further information
Related condition support groups
Menopausal Disorders, Hot Flashes